Nob Hill Therapeutics
Pioneering Respiratory Patient Care
Pioneering Respiratory Patient Care
Nob Hill Therapeutics is a biotechnology startup that is pioneering respiratory patient care with its first-of-its-kind dry powder nebulizer (DryNebTM) inhalation drug delivery platform. The company's mission is to address lower respiratory tract infections and other deadly lung diseases, which are the 5th leading cause of death worldwide. Founded in 2016, Nob Hill Therapeutics operates in the Biotechnology, Life Sciences, and Pharmaceutical industries. The company recently received a $3.00M Series A investment on 06 August 2024 from notable investors including Tech Coast Angels, VIC Technology Venture Development, and Tramway Venture Partners. Nob Hill Therapeutics' focus on innovative respiratory therapies and its recent funding round position it as an intriguing prospect in the biotech industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $3.00M | 3 |
|
06 Aug 2024 |
| Grant | $25.00K | 1 | New Mexico Economic Development Department | 31 Mar 2022 |
| Angel Round | $65.00K | 1 |
|
01 Feb 2022 |
| Seed Round | $30.00K | 1 |
|
05 Nov 2021 |
| Seed Round | $112.50K | - | 01 Nov 2016 |
No recent news or press coverage available for Nob Hill Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
